Search Results - "Fulgenzi, C.A.M."

114TiP Preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV-associated Kaposi sarcoma (StarKap) by Fulgenzi, C.A.M., Dalla Pria, A., Bower, M.D., Pinato, D.J.

Get full text

978P Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B) by Fulgenzi, C.A.M., Huang, Y-H., Saeed, A., Rimassa, L., Schoenlein, M., Piscaglia, F., Kaseb, A., Vogel, A., Bettinger, D., Silletta, M., Kudo, M., Vivaldi, C., Scheiner, B., Ulahannan, S., Galle, P.R., Hsu, W-F., Parisi, A., Chon, H.J., Pinato, D.J., Ang, C.

Get full text

1986P Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry by Mazzocca, A., Orlando, S., Company, J. Aguilar, Morales, C.M. Valverde, Bertulli, R.M., Sandwall, P., Sita-Lumsden, A.R., Bertuzzi, A., Rossi, S., Lee, A.J.X., Murphy, C., Mukherjee, U., Pommeret, F.A., Dettorre, G., Fulgenzi, C.A.M., Gennari, A., Napolitano, A., Vincenzi, B., Pinato, D.J., Cortellini, A.

Get full text

A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions by Cortellini, A., Barrichello, A.P.C., Alessi, J.V., Ricciuti, B., Vaz, V.R., Newsom-Davis, T., Evans, J.S., Lamberti, G., Pecci, F., Viola, P., D’Alessio, A., Fulgenzi, C.A.M., Awad, M.M., Pinato, D.J.

Get full text

T.07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS by Celsa, C., Cabibbo, G., Fulgenzi, C.A.M., Scheiner, B., D'Alessio, A., Manfredi, G.F., Stefanini, B., Marron, T., Saeed, A., Pinter, M., Huang, Y., Pillai, A., Schönlein, M., Von Felden, J., Galle, P.R., Kudo, M., Rimassa, L., Singal, A.G., Chon, H.J., Hsu, W., Vogel, A., Brunetti, L., Pinto, C., Bersanelli, M., Cortellini, A., Cammà, C., Pinato, D.J.

Get full text

Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma by Manfredi, G.F., Fulgenzi, C.A.M., D'Alessio, A., Celsa, C., Stefanini, B., Cheon, J., Ang, C., Marron, T.U., Saeed, A., Wietharn, B., Pressiani, T., Pinter, M., Scheiner, B., Huang, Yi-Hsiang, Phen, S., Naqash, A. Rafeh, Piscaglia, F., Lin, R. Po-Ting, -yen Lin, C., Dalbeni, A., Vivaldi, C., Masi, G., Thimme, R., Vogel, A., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Galle, P.R., Kudo, M., Rimassa, L., Singal, A., Sharma, R., Cortellini, A., Jae Chon, H., Burlone, M., Pirisi, M., Pinato, D.J.

Get full text

112P Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants by Awosika, N.O., Maleki, A., Mehan, A., Manfredi, G.F., Korolewicz, J.A., Fulgenzi, C.A.M., D'Alessio, A., Shakhouri, T., McGovern, K., Rackie, J., Durano, K., Lopes, R., Martinez Del Perral, E. Ferrer, Stefanini, B., Nabbosa, H., Aziz, F., Celsa, C., Evans, J., Cortellini, A., Pinato, D.J.

Get full text

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma by Rapposelli, I.G., Shimose, S., Kumada, T., Okamura, S., Hiraoka, A., Di Costanzo, G.G., Marra, F., Tamburini, E., Forgione, A., Foschi, F.G., Silletta, M., Lonardi, S., Masi, G., Scartozzi, M., Nakano, M., Shibata, H., Kawata, K., Pellino, A., Vivaldi, C., Lai, E., Takata, A., Tajiri, K., Toyoda, H., Tortora, R., Campani, C., Viola, M.G., Piscaglia, F., Conti, F., Fulgenzi, C.A.M., Frassineti, G.L., Rizzato, M.D., Salani, F., Astara, G., Torimura, T., Atsukawa, M., Tada, T., Burgio, V., Rimini, M., Cascinu, S., Casadei-Gardini, A.

“…After the advent of new treatment options for advanced hepatocellular carcinoma (HCC), the identification of prognostic factors is crucial for the selection of…”
Get full text

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials by Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., Santini, D.

“…Colorectal cancer (CRC) is one of the most common cancers; ∼20% of patients have metastases at diagnosis, and 50%-60% subsequently develop metachronous…”
Get full text